Eiger BioPharmaceuticals, Inc. (EIGR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Palo Alto, CA, United States. The current CEO is David Apelian.
EIGR has IPO date of 2014-01-30, 56 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $2.55M.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
